» Articles » PMID: 29492383

Current Indications for Transplantation: Stratification of Severe Heart Failure and Shared Decision-making

Overview
Date 2018 Mar 2
PMID 29492383
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Heart failure (HF) is a complex clinical syndrome that results from structural or functional cardiovascular disorders causing a mismatch between demand and supply of oxygenated blood and consecutive failure of the body's organs. For those patients with stage D HF, advanced therapies, such as mechanical circulatory support (MCS) or heart transplantation (HTx), are potentially life-saving options. The role of risk stratification of patients with stage D HF in a value-based healthcare framework is to predict which subset might benefit from advanced HF (AdHF) therapies, to improve outcomes related to the individual patient including mortality, morbidity and patient experience as well as to optimize health care delivery system outcomes such as cost-effectiveness. Risk stratification and subsequent outcome prediction as well as therapeutic recommendation-making need to be based on the comparative survival benefit rationale. A robust model needs to (I) have the power to discriminate (i.e., to correctly risk stratify patients); (II) calibrate (i.e., to show agreement between the predicted and observed risk); (III) to be applicable to the general population; and (IV) provide good external validation. The Seattle Heart Failure Model (SHFM) and the Heart Failure Survival Score (HFSS) are two of the most widely utilized scores. However, outcomes for patients with HF are highly variable which make clinical predictions challenging. Despite our clinical expertise and current prediction tools, the best short- and long-term survival for the individual patient, particularly the sickest patient, is not easy to identify because among the most severely ill, elderly and frail patients, most preoperative prediction tools have the tendency to be imprecise in estimating risk. They should be used as a guide in a clinical encounter grounded in a culture of shared decision-making, with the expert healthcare professional team as consultants and the patient as an empowered decision-maker in a trustful safe therapeutic relationship.

Citing Articles

Patients' and healthcare professionals' perceived facilitators and barriers for shared decision-making for frail and elderly patients in perioperative care: a scoping review.

Vogel A, Guinemer C, Furstenau D BMC Health Serv Res. 2023; 23(1):197.

PMID: 36829131 PMC: 9960423. DOI: 10.1186/s12913-023-09120-4.


A Heart Failure Model Established by Pressure Overload Caused by Abdominal Aortic Contraction in Rat.

Dai W, Chen Y, Lin S, Chen Q, Cao H Dis Markers. 2022; 2022:4412228.

PMID: 36277986 PMC: 9581619. DOI: 10.1155/2022/4412228.


Development of 3D PVA scaffolds for cardiac tissue engineering and cell screening applications.

Dattola E, Parrotta E, Scalise S, Perozziello G, Limongi T, Candeloro P RSC Adv. 2022; 9(8):4246-4257.

PMID: 35520194 PMC: 9060459. DOI: 10.1039/c8ra08187e.


Silence of LncRNA Protects Cardiomyocytes H9c2 against Hypoxic Injury via Sponging --.

Du J, Yang S, Liu J, Zhang K, Leng J Mol Cells. 2019; 42(5):397-405.

PMID: 31085811 PMC: 6537652. DOI: 10.14348/molcells.2018.0180.


A peripheral blood transcriptome biomarker test to diagnose functional recovery potential in advanced heart failure.

Deng M Biomark Med. 2018; 12(6):619-635.

PMID: 29737882 PMC: 6479277. DOI: 10.2217/bmm-2018-0097.

References
1.
Russell S, Miller L, Pagani F . Advanced heart failure: a call to action. Congest Heart Fail. 2008; 14(6):316-21. DOI: 10.1111/j.1751-7133.2008.00022.x. View

2.
Sinha A, Shahzad K, Latif F, Cadeiras M, Von Bayern M, Oz S . Peripheral blood mononuclear cell transcriptome profiles suggest T-cell immunosuppression after uncomplicated mechanical circulatory support device surgery. Hum Immunol. 2009; 71(2):164-9. DOI: 10.1016/j.humimm.2009.10.012. View

3.
Flint K, Matlock D, Lindenfeld J, Allen L . Frailty and the selection of patients for destination therapy left ventricular assist device. Circ Heart Fail. 2012; 5(2):286-93. PMC: 3869992. DOI: 10.1161/CIRCHEARTFAILURE.111.963215. View

4.
Burton D, Faragher R . Cellular senescence: from growth arrest to immunogenic conversion. Age (Dordr). 2015; 37(2):27. PMC: 4365077. DOI: 10.1007/s11357-015-9764-2. View

5.
Dunlay S, Park S, Joyce L, Daly R, Stulak J, McNallan S . Frailty and outcomes after implantation of left ventricular assist device as destination therapy. J Heart Lung Transplant. 2014; 33(4):359-65. PMC: 3966938. DOI: 10.1016/j.healun.2013.12.014. View